A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study
- 1 September 2018
- journal article
- editorial
- Published by Elsevier BV in European Urology Focus
- Vol. 4 (5), 636-638
- https://doi.org/10.1016/j.euf.2018.08.016
Abstract
No abstract availableFunding Information
- National Cancer Institute (HHSN261201200031I, HHSN26100006)
This publication has 11 references indexed in Scilit:
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerNew England Journal of Medicine, 2016
- Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS CohortJournal of Urology, 2016
- Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate CancerJournal of Clinical Oncology, 2015
- Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate CancerJournal of Urology, 2014
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancerCancer Immunology, Immunotherapy, 2013
- Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS StudyEuropean Urology, 2013
- Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesCancer Immunology, Immunotherapy, 2011
- Impact of Tumour Volume on the Potential Efficacy of Therapeutic VaccinesCurrent Oncology, 2011
- Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins ExperienceJournal of Clinical Oncology, 2011
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009